文献速递肝病

索磷布韦-维帕他韦-伏西拉韦联合或不联合利巴韦林治疗基因1型丙型肝炎病毒感染经直接抗病毒药物治疗失败的患者

Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
PubMed 文献 · Hepatology · 2017-05-03

这项在美国单中心开展的2期开放标签研究,将既往直接抗病毒药物方案治疗未获持续病毒学应答的基因1型丙型肝炎病毒感染患者随机分配,接受索磷布韦-维帕他韦-伏西拉韦固定剂量复方片联合或不联合利巴韦林治疗12周。单药组24/24例(100%;95%CI 86-100)和联合利巴韦林组24/25例(96%;95%CI 80-100)获得治疗结束后12周持续病毒学应答。

要点

  • 索磷布韦-维帕他韦-伏西拉韦单药组24/24例(100%)获得SVR12。
  • 联合利巴韦林组24/25例(96%)获得SVR12。
  • 无患者因不良事件停用索磷布韦-维帕他韦-伏西拉韦治疗。

核心结论

  • 索磷布韦-维帕他韦-伏西拉韦固定剂量复方耐受良好,对既往接受过直接抗病毒药物治疗的基因1型丙型肝炎病毒感染患者可有效实现病毒学应答。

研究设计与样本

  • 2期开放标签研究,在美国单中心开展,纳入既往直接抗病毒药物方案治疗未获持续病毒学应答的基因1型丙型肝炎病毒感染患者,随机接受索磷布韦-维帕他韦-伏西拉韦固定剂量复方片联合或不联合利巴韦林治疗12周,按肝硬化和既往非结构蛋白5A抑制剂暴露分层,主要疗效终点为治疗结束后12周持续病毒学应答(SVR12)。

主要发现

  • 索磷布韦-维帕他韦-伏西拉韦单药组24/24例(100%;95%CI 86-100)获得SVR12。
  • 索磷布韦-维帕他韦-伏西拉韦联合利巴韦林组24/25例(96%;95%CI 80-100)获得SVR12。
  • 无患者因不良事件停用索磷布韦-维帕他韦-伏西拉韦治疗。
  • 单药组最常见不良事件为腹泻和支气管炎;联合利巴韦林组最常见不良事件为乏力、贫血、胃肠炎和恶心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who fail direct-acting antiviral (DAA)-based regimens remains unknown. In this phase 2, open-label study conducted at a single center in the United States, patients with HCV genotype 1 infection who previously failed to achieve sustained virological response (SVR) on a DAA-based regimen were randomized to receive treatment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin (RBV) for 12 weeks. Patients were stratified by their cirrhosis and past nonstructural protein (NS) 5A inhibitor exposure. The primary efficacy endpoint was the proportion of patients with SVR at 12 weeks after treatment (SVR12). SVR12 was achieved by 24 of 24 patients (100%; 95% confidence interval [CI], 86-100) receiving sofosbuvir-velpatasvir-voxilaprevir alone and 24 of 25 (96%; 95% CI, 80-100) receiving the same treatment with RBV. None of the patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of an adverse event (AE). The most commonly reported AEs with sofosbuvir-velpatasvir-voxilaprevir alone were diarrhea and bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir plus RBV were fatigue, anemia, gastroenteritis, and nausea. CONCLUSION: A fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir was well tolerated and effective at achieving virological response in patients with HCV genotype 1 infection and past DAA treatment experience. (Hepatology 2017;65:1803-1809).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lawitz E, Poordad F, Wells J, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017. PMID: 28220512. doi:10.1002/hep.29130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。